Literature DB >> 19306039

Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy.

Chiara S M Straathof1, W C G Truus Overweg-Plandsoen, Gert Jan van den Burg, Anneke J van der Kooi, Jan J G M Verschuuren, Imelda J M de Groot.   

Abstract

Corticosteroids are effective in improving motor function in Duchenne muscular dystrophy (DMD) patients within 6 months-2 years of treatment initiation, but there is as yet no consensus on which treatment scheme is the best. We retrospectively analyzed data of 35 DMD patients who were treated with prednisone 0.75 mg/kg per day intermittently 10 days on/10 days off. Prednisone was started during the ambulant phase at age 3.5-9.7 years (median 6.5 years). The median period of treatment was 27 months (range 3-123 months). The median age at which ambulation was lost was 10.8 years (mean 10.9 years; 95% confidence interval 10.0-11.8 years). Nine patients (26%) had excessive weight gain. Eight boys (21%) had a bone fracture, which was when four of these eight children lost the ability to walk. Treatment was stopped in two obese patients, two hyperactive boys and one patient following a fracture. Our data suggest that prednisone 10 on/10 off has relatively few side effects and extends the ambulant phase by 1 year compared to historical controls.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306039     DOI: 10.1007/s00415-009-5012-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Challenges in drug development for muscle disease: a stakeholders' meeting.

Authors:  Jerry R Mendell; Cristina Csimma; Craig M McDonald; Diana M Escolar; Scott Janis; John D Porter; Sharon E Hesterlee; R Rodney Howell
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

3.  Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.

Authors:  Sunil Pradhan; Debabrata Ghosh; Niraj Kumar Srivastava; Ashok Kumar; Balraj Mittal; Chandra Mani Pandey; Uttam Singh
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

4.  [Guideline on the use of corticosteroids in Duchenne muscular dystrophy from paediatric neurologists, neurologists and rehabilitation physicians].

Authors:  I J M de Groot
Journal:  Ned Tijdschr Geneeskd       Date:  2006-03-25

5.  Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.

Authors:  Ernesto A C Beenakker; Johanna M Fock; Marja J Van Tol; Natalia M Maurits; Hendrik M Koopman; Oebele F Brouwer; Johannes H Van der Hoeven
Journal:  Arch Neurol       Date:  2005-01

6.  Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients.

Authors:  Ernesto A C Beenakker; Natalia M Maurits; Johanna M Fock; Oebele F Brouwer; Johannes H van der Hoeven
Journal:  Eur J Paediatr Neurol       Date:  2005-08-15       Impact factor: 3.140

7.  Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.

Authors:  W D Biggar; L Politano; V A Harris; L Passamano; J Vajsar; B Alman; A Palladino; L I Comi; G Nigro
Journal:  Neuromuscul Disord       Date:  2004-09       Impact factor: 4.296

8.  An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.

Authors:  Maria Kinali; Eugenio Mercuri; Marion Main; Francesco Muntoni; Victor Dubowitz
Journal:  Neuromuscul Disord       Date:  2002-10       Impact factor: 4.296

9.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.

Authors:  W M King; R Ruttencutter; H N Nagaraja; V Matkovic; J Landoll; C Hoyle; J R Mendell; J T Kissel
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

10.  Deflazacort in Duchenne dystrophy: study of long-term effect.

Authors:  C Angelini; E Pegoraro; E Turella; M T Intino; A Pini; C Costa
Journal:  Muscle Nerve       Date:  1994-04       Impact factor: 3.217

View more
  13 in total

1.  Current treatment and management of dystrophinopathies.

Authors:  Nathalie Goemans; Gunnar Buyse
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

2.  Diagnostic Accuracy of Phenotype Classification in Duchenne and Becker Muscular Dystrophy Using Medical Record Data1.

Authors:  Jennifer G Andrews; Molly M Lamb; Kristin Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Christopher Cunniff; Shree Pandya; Deborah J Fox
Journal:  J Neuromuscul Dis       Date:  2018

3.  Bone is functionally impaired in dystrophic mice but less so than skeletal muscle.

Authors:  Susan A Novotny; Gordon L Warren; Angela S Lin; Robert E Guldberg; Kristen A Baltgalvis; Dawn A Lowe
Journal:  Neuromuscul Disord       Date:  2011-01-21       Impact factor: 4.296

4.  Neuromuscular disorders and 2010: recent advances.

Authors:  Anna Sarkozy; Hanns Lochmüller
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

5.  Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation.

Authors:  Saskia L S Houwen-van Opstal; Lotte Heutinck; Merel Jansen; Yvonne D Krom; Edith H C Cup; Jos G M Hendriksen; Michel A A P Willemsen; Jan J G M Verschuuren; Erik H Niks; Imelda J M de Groot
Journal:  Muscle Nerve       Date:  2021-09-09       Impact factor: 3.852

6.  Differentiation of Pediatric-Onset Duchenne and Becker Muscular Dystrophy Subphenotypes Using Data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet).

Authors:  Jennifer G Andrews; Molly M Lamb; Kristin M Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Shree Pandya
Journal:  J Neuromuscul Dis       Date:  2022

7.  Musculoskeletal response of dystrophic mice to short term, low intensity, high frequency vibration.

Authors:  S A Novotny; M D Eckhoff; B C Eby; J A Call; D Nuckley; D A Lowe
Journal:  J Musculoskelet Neuronal Interact       Date:  2013-12       Impact factor: 2.041

8.  Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.

Authors:  Molly M Lamb; Nancy A West; Lijing Ouyang; Michele Yang; David Weitzenkamp; Katherine James; Emma Ciafaloni; Shree Pandya; Carolyn DiGuiseppi
Journal:  J Pediatr       Date:  2016-03-30       Impact factor: 4.406

9.  Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice.

Authors:  Sarah K Gray; Meghan E McGee-Lawrence; Jennifer L Sanders; Keith W Condon; Chung-Jui Tsai; Seth W Donahue
Journal:  Bone       Date:  2012-05-11       Impact factor: 4.398

10.  The effects of glucocorticoid and voluntary exercise treatment on the development of thoracolumbar kyphosis in dystrophin-deficient mice.

Authors:  Daniel Brereton; Jeffrey Plochocki; Daniel An; Jeffrey Costas; Erin Simons
Journal:  PLoS Curr       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.